Video

Dr. Goetz on the ELAINE-1 Trial of Lasofoxifene in ESR1-Mutated, ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the progression-free survival (PFS) benefit derived with lasofoxifene in patients with ESR1-mutated, estrogen receptor (ER)–positive/HER2-negative metastatic breast cancer.

The phase 2 ELAINE-1 trial (NCT03781063) compared the safety and efficacy of lasofoxifene with that of fulvestrant (Faslodex) in this patient population. Enrolled patients were required to have experienced disease progression on an aromatase inhibitor and a CDK4/6 inhibitor, Goetz says. Participants were randomly assigned to receive oral lasofoxifene at 5 mg daily or 500 mg of fulvestrant administered intramuscularly on days 1, 15, and 29, and every 4 weeks thereafter, Goetz adds.

Data presented at the 2022 ESMO Congress showed that treatment with lasofoxifene (n = 52) resulted in a median PFS of 6.04 months (95% CI, 2.82-8.04) compared with 4.04 months (95% CI, 2.93-6.04) with fulvestrant (n = 51; HR, 0.699; 95% CI, 0.445-1.125; P= .138). Although it was not determined to be statistically significant, the difference in median PFS was a positive signal, and there was clear evidence of antitumor activity with lasofoxifene in this population, Goetz concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity